PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicentric, randomized, double blind, placebo controlled Phase II
clinical study to compare the safety and efficacy of PMZ-1620 therapy along with standard
supportive care in subjects with mild to moderate Alzheimer's disease.